GlassScriptPhysician profile
Stephen B Serynek
NPI 1285896688
$2,424.32
in general payments reported to CMS, 2019-2025
18 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $248 · 2021: $450 · 2022: $430 · 2023: $256 · 2024: $324 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $546.35 | 2019-2025 | |
| Boston Scientific Corporation | $414.18 | 2019-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $184.81 | 2020-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.48 | 2019-2020 | |
| Amgen INC. | $148.67 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $143.00 | 2021 | |
| Heartflow, INC. | $140.43 | 2024 | |
| Pfizer INC. | $136.16 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $96.37 | 2019-2021 | |
| Novo Nordisk INC | $47.06 | 2021-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $46.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $40.47 | 2019 | |
| Abbott Laboratories | $40.12 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coala Life INC | $23.73 | 2021 | |
| Althera Pharmaceuticals LLC | $18.56 | 2021 | |
| Medtronic, INC. | $15.62 | 2023 | Micra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Serynek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.